Cisplatin is one of the most effectively used chemotherapeutic agents for cancer treatment. However, in humans, important cytotoxic side effects are observed including dose-limiting renal damage and profound gastrointestinal symptomatology. The toxic responses to cisplatin in mice are similar to those in human patients. Here, we evaluated whether the acid sphingomyelinase (Asm) mediates at least some of the toxic in vivo effects of cisplatin. To this end, we determined the toxic effects of a single intraperitoneal dose of cisplatin (27 mg/kg) in wild type (Asm þ / þ ) and Asm-deficient mice (Asm
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Cisplatin (cis-diamminedichloroplatinum or CDDP) is an anticancer agent widely used in the treatment of solid tumors (Loehrer and Einhorn, 1984) , although its use is limited by severe toxic side effects. Indeed, cisplatin exerts toxic effects on normal tissues, including renal tubular necrosis and dose-dependent damage of the gastrointestinal epithelium in mice. These damages are very similar to those observed in humans, thus providing evidence of the usefulness of the mouse model to predict toxicological responses to anticancer drugs (Harrison, 1981) . Definition of the molecular mechanisms of cisplatin-induced toxicity is important for the development of adjunctive therapies to prevent cisplatin toxicity and to understand mechanisms of cisplatin resistance. Although DNA is considered as the primary target of cisplatin, this anticancer agent has also been shown to interact with the plasma membrane, thereby reducing the activity of certain ion channels (Grunicke and Hofmann, 1992) . Recently, we have demonstrated that cisplatin induces apoptosis through the activation of acid sphingomyelinase (Asm) (Lacour et al., 2004; Rebillard et al., 2007) . This enzyme, which converts sphingomyelin to ceramide, has also been shown to be activated by many proapoptotic receptors (CD95/Fas and TNF-R), stress stimuli (irradiation and ultraviolet light) and antiproliferative agents (rituximab) (Santana et al., 1996; Huang et al., 1997; Gulbins and Grassme, 2002; Gulbins and Kolesnick, 2003; Bezombes et al., 2004) .
At present, the role of Asm in the toxicity of anticancer drugs in vivo requires definition. It has been shown that ex vivo Asm-deficient mice (Asm À/À ) oocytes were resistant to doxorubicin (Morita et al., 2000) . Furthermore, Asm À/À mice were protected from radiation-induced damage in the lung (Santana et al., 1996) , small intestine (Paris et al., 2001 ) and brain (Pena et al., 2000) . These results led us to study the role of Asm in cisplatin toxicity in vivo by using Asm À/À mice in comparison with syngenic C57BL/6 wild-type mice (Horinouchi et al., 1995) .
Earlier publications revealed an LD 50 of cisplatin (18 mg/kg) in mice (Prestayko et al., 1979) . At a dose of 14 mg/kg, cisplatin induced reversible gastrointestinal alterations (Harrison, 1981) . This fact led us to choose a higher dose of cisplatin (27 mg/kg), which caused severe toxicity with acute renal failure and death of the mice on days 4-5 after cisplatin injection.
We observed a tissue-specific activity of cisplatin toxicity in wild-type (Asm þ / þ ) mice. The most dramatic histological changes were observed in the small intestine (ileum) and thymus of these mice. Villi in ileum were shortened with a reduction in the number of goblet cells, and an increase of apoptotic bodies following 72 h of cisplatin treatment (Figure 1a ), whereas intestinal villi of mice treated with vehicle remained intact. Similar cisplatin toxic effects were previously observed in the small intestine of B6D2F1 (Harrison, 1981) , CBA (Allan and Smyth, 1986) and BALB/c mice (Tamaki et al., 2003) . We also detected an increase in the number of apoptotic bodies with a reduction of lymphocytic and thymic cells in the thymus (Figure 1b) . No histological changes were observed in the liver, lung and bone marrow tissues of Asm þ / þ mice treated with a single intraperitoneal dose of cisplatin (27 mg/kg) for 72 h (data not shown).
Next, we studied the involvement of Asm in cisplatininduced toxicity in the small intestine and thymus by comparing the toxic effect of a single intraperitoneal injection of cisplatin (27 mg/kg) in Asm þ / þ and Asm In summary, our data show for the first time that cisplatin treatment caused injuries in the small intestine and thymus that are absent in Asm À/À mice. These effects are not because of a decrease in platin level in serum of Asm To achieve a detailed characterization of apoptosis in the small intestine, we performed time course experiments following cisplatin treatment. TUNEL staining revealed many apoptotic cells mainly in the lamina propria of villi as early as 3 h after CDDP treatment of Asm To collect tissues, mice were killed by cervical dislocation, the organs removed, fixed in 4% paraformaldehyde and embedded in paraffin. Transverse tissue sections were obtained, attached to polylysine-treated slides, deparaffinized by heating at 90 1C for 10 min and at 60 1C for 5 min, followed by two xylene washes for 5 min, and staining with hematoxylin-eosin according to a standard protocol. One representative of hematoxylin-eosin staining of tissue sections is shown ( Â 400 magnification).
for irradiation (Paris et al., 2001) . To test this hypothesis, we visualized in the small intestine (ileum) vascular endothelial cells and apoptotic cells by staining with factor VIII Von Willebrand and TUNEL assay, respectively. The results revealed massive apoptosis of endothelial cells in Asm þ / þ mice treated for 3 h with CDDP (indicated by the co-staining in yellow), which was almost completely absent in Asm À/À or vehicletreated mice (Figure 3b) . No apoptotic cells (in green) were detected in the epithelium (Figure 3b ) 3 h after þ / þ and Asm À/À mice were treated with cisplatin (27 mg/kg) as described above. The Smpd1-deficient mouse was kindly provided by Dr R Kolesnick, MSKCC, USA. All experimental protocols were approved by the ethics committee for animal experimentation. Asm þ / þ and Asm À/À mice (8-to 12-weeks old , weighing 20-25 g) were maintained on a standard diet and water was freely available. Tissue sections were stained with hematoxylin-eosin or with terminal deoxynucleotidyl transferase (TdT)-mediated nick end labeling assay to detect in situ DNA strand breaks in apoptotic cells according to the manufacturer's instructions (Roche Diagnostics France SA, Meylan, France). Representative hematoxylin-eosin or terminal deoxynucleotidyl transferase (TdT)-mediated nick end labeling stainings are shown ( Â 400 magnification). (c) Frequency histograms of apoptotic cells in the thymus are shown. Thymus were removed 72 h after cisplatin treatment of each of the six Asm þ / þ and Asm À/À mice and stained for apoptosis by terminal deoxynucleotidyl transferase (TdT)-mediated nick end labeling assay. Apoptotic cells were scored in 25 different fields. Data represent mean scores from three experiments. Statistical analyses were performed using the unilateral Student's t-test considering the variances as unequal (Supplementary Data). versus CDDP 3 h, Po0.001), although the percentage of crypts/villi units with apoptotic epithelial cells increased (a 60% increase in the percentage of units with 3-5 apoptotic cells, CDDP 12 h versus 3 h, Po0.001) (Figure 3c ). In contrast, both endothelial and epithelial cells of the small intestine were almost completely protected in Asm À/À mice from CDDP-induced cytotoxicity 36 h after CDDP treatment (Figure 3c ). þ / þ and p53 À/À mice and co-stained with factor VIII Von Willebrand (in red) and terminal deoxynucleotidyl transferase (TdT)-mediated nick end labeling assay (in green) ( Â 400 magnification).
Asm-deficient mice and cisplatin toxicity
These data suggest that cisplatin induces small intestine toxicity through apoptosis of endothelial cells before columnar epithelial cells. Thus, the alteration of the microcirculation in the crypt/villus units may permit CDDP-mediated apoptosis in epithelial cells and/or may directly trigger death of these cells. Similar results were observed in the thymus of Asm þ / þ mice with massive apoptosis of endothelial cells 3 or 12 h after CDDP treatment (Figure 3d , indicated by the co-staining in yellow), followed by massive apoptosis of thymocytes 36 or 72 h after CDDP treatment (Figure 3d , fragmented nuclei stained in green).
Cisplatin cytotoxicity has been previously shown to be p53-dependent (Vasey et al., 1996) . To study the involvement of p53 protein in cisplatin toxicity in the small intestine and thymus, we treated p53
À/À mice with a 27 mg/kg dose of cisplatin. Interestingly, co-stainings with factor VIII Von Willebrand and TUNEL revealed apoptosis of endothelial cells in the small intestine ( Figure 4b ) and thymus ( Figure 4d ) of p53 þ / þ mice treated with cisplatin for 3 h, which was absent in p53 À/À mice. After 36 h of cisplatin treatment, no lesion in the small intestine and thymus of p53 À/À mice was observed (Figures 4a and c) .
Recently, we have shown that cisplatin treatment rapidly activates Asm independently of DNA damage in the course of cisplatin-induced apoptosis in p53-mutated HT29 human colon cancer cells (Rebillard et al., 2007) .
Our data demonstrate for the first time that another cell death pathway dependent on Asm could account for cisplatin toxicity in vivo and suggest that mechanisms leading to cisplatin resistance in tumor cells may also arise through alterations in Asm-dependent apoptotic pathway. Moreover, p53 signaling is also involved in cisplatin endothelial damage in the small intestine and thymus. Our results are in agreement with those of Sansom and Clarke (2002) showing that p53 deficiency protected the intestinal stem cell compartment against cisplatin-mediated lethality. They also suggest that Asm deficiency may result in the same protection against cisplatin toxicity. In summary, our data suggest for the first time that Asm/p53 dually regulate cisplatin-induced damage in the small intestine and thymus. It is intriguing to speculate whether cisplatin sequentially activates p53 and Asm to trigger death or whether both pathways are independently required to mediate death by cisplatin. However, a detailed analysis of the interactions of the two pathways is beyond the focus of this paper and requires further study.
